Peer-reviewed veterinary case report
Pancreatitis enzyme levels in dogs treated for lymphoma
By Wright, Zachary et al.·Published in Canadian journal of veterinary research = Revue canadienne de recherche veterinaire·2009·Department of Small Animal Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A pilot study evaluating changes in pancreatic lipase immunoreactivity concentrations in canines treated with L-asparaginase (ASNase), vincristine, or both for lymphoma.
- Species:
- dog
Plain-English summary
A group of dogs with lymphoma received chemotherapy treatments, including L-asparaginase (ASNase) and vincristine, to see if these drugs caused pancreatitis, which can be a serious condition. The study found that dogs treated with ASNase alone did not show signs of pancreatitis, and their pancreatic enzyme levels remained stable. However, some dogs that received both ASNase and vincristine had elevated enzyme levels, indicating potential pancreatitis. Overall, ASNase did not appear to cause pancreatitis in the dogs studied, but more research is needed to confirm these findings.
People also search for: dog lymphoma treatment · pancreatitis symptoms in dogs · L-asparaginase side effects in dogs
Abstract
L-asparaginase (ASNase) is a common chemotherapy agent for the treatment of lymphoid malignancies. L-asparaginase has been reported to cause clinical pancreatitis in both humans and canines. Canine pancreatic lipase immunoreactivity (cPLI) is now a common diagnostic tool for evaluating pancreatitis in dogs. A total of 52 dogs were enrolled into this study. Canine pancreatic lipase immunoreactivity (cPLI) concentrations were evaluated before and after administration of ASNase, vincristine, or both. All dogs enrolled in the study were evaluated for signs compatible with clinical pancreatitis. No dogs receiving ASNase alone showed evidence of clinical pancreatitis after administration. Also, there was no statistically significant change in cPLI concentrations before or after treatment. Fourteen percent of dogs that received both vincristine and ASNase concurrently had elevated concentrations of cPLI after treatment. Of the 11 dogs with clinical signs compatible with pancreatitis after any chemotherapy treatment, no dog had a cPLI concentration > 400 microg/dL. In conclusion, ASNase did not cause clinical pancreatitis in this cohort of dogs but larger sample sizes are required to further validate this data.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/19436578/